ES2081517T3 - ((arilalquilpiperidin-4-il)metil)-2-alfa,3,4,5-tetrahidro-1(2h)-acenaftilen-1-onas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos. - Google Patents

((arilalquilpiperidin-4-il)metil)-2-alfa,3,4,5-tetrahidro-1(2h)-acenaftilen-1-onas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.

Info

Publication number
ES2081517T3
ES2081517T3 ES92109467T ES92109467T ES2081517T3 ES 2081517 T3 ES2081517 T3 ES 2081517T3 ES 92109467 T ES92109467 T ES 92109467T ES 92109467 T ES92109467 T ES 92109467T ES 2081517 T3 ES2081517 T3 ES 2081517T3
Authority
ES
Spain
Prior art keywords
arilalquilpiperidin
acenaftilen
onas
tetrahydro
medicines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92109467T
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Bettina Spahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2081517T3 publication Critical patent/ES2081517T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE PRESENTAN VARIOS COMPUESTOS DE LA FORMULA DONDE X ES HIDROGENO, ALKILO INFERIOR, ALCOXI INFERIOR, HIDROXI O NITRO; Y ES HIDROGENO O ALCOXI INFERIOR; O ALTERNATIVAMENTE, X E Y COMBINADOS ENTRE SI FORMAN EL GRUPO -OCH20 IONES DE X E Y EN LA UNIDAD DEL ANILLO DE BENCENO DEBEN SER ADYACENTES ENTRE SI; Z ES HIDROGENO, ALKILO INFERIOR, ALCOXI INFERIOR, HIDROXI, HALOGENO O NITRO Y N ES 0 O 1, CUYOS COMPUESTOS SON UTILES PARA ALIVIAR DISTINTAS DISFUNCIONES DE LA MEMORIA CARACTERIZADAS POR UN DEFICIT COLINERGICO COMO POR EJEMPLO LA ENFERMEDAD DE ALZHEIMER.
ES92109467T 1991-06-07 1992-06-04 ((arilalquilpiperidin-4-il)metil)-2-alfa,3,4,5-tetrahidro-1(2h)-acenaftilen-1-onas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos. Expired - Lifetime ES2081517T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/713,249 US5106856A (en) 1991-06-07 1991-06-07 [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds

Publications (1)

Publication Number Publication Date
ES2081517T3 true ES2081517T3 (es) 1996-03-16

Family

ID=24865395

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92109467T Expired - Lifetime ES2081517T3 (es) 1991-06-07 1992-06-04 ((arilalquilpiperidin-4-il)metil)-2-alfa,3,4,5-tetrahidro-1(2h)-acenaftilen-1-onas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.

Country Status (23)

Country Link
US (1) US5106856A (es)
EP (1) EP0517221B1 (es)
JP (1) JP2961013B2 (es)
KR (1) KR100234445B1 (es)
AT (1) ATE131814T1 (es)
AU (1) AU646784B2 (es)
CA (1) CA2070714A1 (es)
CZ (1) CZ284591B6 (es)
DE (1) DE69206889T2 (es)
DK (1) DK0517221T3 (es)
ES (1) ES2081517T3 (es)
FI (1) FI101297B (es)
GR (1) GR3018558T3 (es)
HU (1) HU217967B (es)
IE (1) IE72199B1 (es)
IL (1) IL102118A (es)
MX (1) MX9202736A (es)
NO (1) NO178889C (es)
NZ (1) NZ243013A (es)
PL (1) PL169423B1 (es)
RU (1) RU2043989C1 (es)
TW (1) TW206214B (es)
ZA (1) ZA924109B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW248556B (es) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589934A (en) * 1950-08-24 1952-03-18 Abbott Lab 2-aminomethyl-tetrahydroacenapthones-1 and their preparation
US3391178A (en) * 1964-12-30 1968-07-02 Ernest E. Campaigne Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
IL102118A0 (en) 1993-01-14
NO922223D0 (no) 1992-06-05
DE69206889T2 (de) 1996-05-30
CS171392A3 (en) 1992-12-16
EP0517221B1 (en) 1995-12-20
AU646784B2 (en) 1994-03-03
TW206214B (es) 1993-05-21
KR100234445B1 (ko) 1999-12-15
KR930000483A (ko) 1993-01-15
JPH06116237A (ja) 1994-04-26
PL294803A1 (en) 1993-07-26
ZA924109B (en) 1993-02-24
PL169423B1 (pl) 1996-07-31
EP0517221A1 (en) 1992-12-09
IE72199B1 (en) 1997-04-09
AU1801592A (en) 1992-12-10
GR3018558T3 (en) 1996-03-31
US5106856A (en) 1992-04-21
IE921840A1 (en) 1992-12-16
FI922592A (fi) 1992-12-08
DK0517221T3 (da) 1996-04-22
NO922223L (no) 1992-12-08
HUT65605A (en) 1994-07-28
HU9201887D0 (en) 1992-08-28
NZ243013A (en) 1995-04-27
FI101297B1 (fi) 1998-05-29
DE69206889D1 (de) 1996-02-01
CA2070714A1 (en) 1992-12-08
IL102118A (en) 1996-05-14
HU217967B (hu) 2000-05-28
RU2043989C1 (ru) 1995-09-20
FI101297B (fi) 1998-05-29
NO178889B (no) 1996-03-18
ATE131814T1 (de) 1996-01-15
JP2961013B2 (ja) 1999-10-12
CZ284591B6 (cs) 1999-01-13
FI922592A0 (fi) 1992-06-04
MX9202736A (es) 1993-01-01
NO178889C (no) 1996-06-26

Similar Documents

Publication Publication Date Title
ES2081517T3 (es) ((arilalquilpiperidin-4-il)metil)-2-alfa,3,4,5-tetrahidro-1(2h)-acenaftilen-1-onas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ES2094840T3 (es) 1-(pirido(3,4-b)-1,4-oxazinil-4-il)-1h-indoles, compuestos intermedios y un procedimiento para su preparacion, y su uso como medicamentos.
ES2109953T3 (es) 1,2,3,4-tetrahidrociclopent(b)indoles, 1,2,3,3a,4,8a-hexahidrociclopent(b)indoles sustituidos y compuestos relacionados, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
DK613687A (da) Kondenserede heterocycliske tetrahydroaminoquinolinoler og beslaegtede forbindelser, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
FI895288A0 (fi) 1,2,3,4-tetrahydro-1,9-akridinaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ES2064533T3 (es) Acido(1,2,3,4-tetrahidro-9-acridinimino)-ciclohexanocarboxilico y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
ES2096800T3 (es) Benzo(b)tiofen-3-il-piperazinas, un procedimiento para su preparacion y su uso como medicamentos.
IL111404A (en) Pharmaceutical compositions for the enhancement ofmemory and cognition comprising 3-aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles and some such novel compounds
MX25922A (es) Pirido (3,4-b) pirrolo (1,2-e)(1,4,5)oxadiazepinasy compuestos analogos relacionados un procedimiento para su preparacion y su uso como medicamentos
ES2072334T3 (es) Derivados de 4,5,5a,6-tetrahidro-3h-isoxazolo(5,4,3-kl)acridinas, un procedimiento para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517221

Country of ref document: ES